Nicholas Investment Partners Sells Shares of Mirion Technologies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MIR?
Source: Fool
- Share Reduction Details: Nicholas Investment Partners disclosed in an SEC filing that it sold 592,382 shares of Mirion Technologies in Q1 2026, valued at approximately $13.36 million, indicating a cautious outlook on the company's future performance.
- Holding Value Decline: As of March 31, the value of Mirion's holdings fell by $14.11 million to $916,078, reflecting market concerns over its stock price, which may impact investor confidence.
- Performance Metrics: Mirion Technologies reported a 27.5% year-over-year revenue increase to $257.6 million in the latest quarter, with orders surging 42%, indicating accelerating growth in the nuclear sector, although it posted a GAAP net loss of $3.4 million, raising concerns about profitability.
- Market Outlook: Despite profitability challenges, Mirion Technologies has potential growth opportunities driven by increased nuclear infrastructure spending and rising demand for radiation monitoring systems, suggesting it may be positioned for a larger growth trajectory in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIR
Wall Street analysts forecast MIR stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.920
Low
29.00
Averages
30.60
High
34.00
Current: 18.920
Low
29.00
Averages
30.60
High
34.00
About MIR
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Share Reduction Details: Nicholas Investment Partners disclosed in an SEC filing that it sold 592,382 shares of Mirion Technologies in Q1 2026, valued at approximately $13.36 million, indicating a cautious outlook on the company's future performance.
- Holding Value Decline: As of March 31, the value of Mirion's holdings fell by $14.11 million to $916,078, reflecting market concerns over its stock price, which may impact investor confidence.
- Performance Metrics: Mirion Technologies reported a 27.5% year-over-year revenue increase to $257.6 million in the latest quarter, with orders surging 42%, indicating accelerating growth in the nuclear sector, although it posted a GAAP net loss of $3.4 million, raising concerns about profitability.
- Market Outlook: Despite profitability challenges, Mirion Technologies has potential growth opportunities driven by increased nuclear infrastructure spending and rising demand for radiation monitoring systems, suggesting it may be positioned for a larger growth trajectory in the future.
See More
- Significant Order Growth: Mirion Technologies reported a 42% increase in orders for Q1 2026, reaching $288 million, with a 19% rise to $241 million excluding M&A, indicating strong demand in the nuclear sector and the company's competitive edge in this market.
- Revenue and Profit Performance: Total revenue for the first quarter was $258 million, up 27.5%, with approximately 21% of this growth attributed to the Paragon acquisition, while adjusted EBITDA stood at $54 million, reflecting the company's profitability during its expansion phase.
- Optimistic Future Outlook: The CFO projected a 15% to 20% increase in orders for Q2 compared to Q1 and reaffirmed the unchanged financial guidance for 2026, despite facing tariff impacts from China, demonstrating management's confidence in future growth.
- Strategic Investments and Market Opportunities: Through the acquisitions of Paragon and Certrec, Mirion has enhanced its product and service offerings, which are expected to drive long-term growth, particularly in the small modular reactor (SMR) market, further solidifying its market position.
See More
- Earnings Beat: Mirion Technologies reported a Q1 non-GAAP EPS of $0.10, beating expectations by $0.01, indicating strong market performance and boosting investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $257.6 million, a 27.5% year-over-year increase, surpassing market expectations by $12.83 million, reflecting sustained demand in the nuclear and industrial technology sectors.
- 2026 Outlook: Mirion reaffirmed its total revenue growth target for 2026 at 22% to 24%, with organic revenue growth projected between 5% and 7%, demonstrating confidence in future growth and clear strategic planning.
- Adjusted EPS Guidance: The adjusted EPS guidance is set at approximately $0.48 to $0.55, below the consensus of $0.55, primarily due to the impact of a one-time CEO retention grant, indicating strategic considerations in executive incentives.
See More
- Earnings Announcement Schedule: Mirion Technologies is set to announce its Q1 earnings on April 28th after market close, with consensus EPS estimate at $0.09, reflecting a 10% year-over-year decline, and revenue estimate at $245.07 million, indicating a 21.3% year-over-year increase.
- Historical Performance Review: Over the past two years, Mirion has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, demonstrating relative stability in financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have experienced no upward revisions and four downward adjustments, indicating a cautious market outlook on the company's future performance.
- Future Growth Outlook: Mirion projects revenue growth of 22% to 24% in 2026, while expanding its nuclear power exposure through the acquisitions of Paragon and Certrec, highlighting its strategic intent for industry expansion.
See More
- Earnings Release Schedule: Mirion will release its Q1 2026 financial results after market close on April 28, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to bolster investor confidence.
- Conference Call Timing: Following the earnings release, Mirion will host a conference call on April 29, 2026, at 10:00 am ET, where participants can dial in to discuss the financial results and address investor inquiries, enhancing engagement with stakeholders.
- Replay Service Availability: A telephonic replay of the conference call will be available until May 13, 2026, ensuring that investors who cannot attend live can access critical information, thereby improving information accessibility and investor relations.
- Company Background Overview: Mirion is a global leader in radiation safety with approximately 3,200 employees operating in 12 countries, focusing on providing innovative solutions for nuclear medicine and radiation therapy, underscoring its significant role in the industry.
See More









